Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2017 2
2018 1
2019 3
2020 2
2022 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Breakthrough TB among people living with HIV on TB preventive therapy.
Nyangu S, Kagujje M, Mwaba I, Luhanga D, Hambwalula R, Maliko S, Mushili T, Mwamba E, Mulai M, Muyoyeta M. Nyangu S, et al. Among authors: mwamba e. Public Health Action. 2022 Dec 21;12(4):153-158. doi: 10.5588/pha.22.0016. Public Health Action. 2022. PMID: 36561906 Free PMC article.
New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice.
Lindner AK, Lejon V, Chappuis F, Seixas J, Kazumba L, Barrett MP, Mwamba E, Erphas O, Akl EA, Villanueva G, Bergman H, Simarro P, Kadima Ebeja A, Priotto G, Franco JR. Lindner AK, et al. Among authors: mwamba e. Lancet Infect Dis. 2020 Feb;20(2):e38-e46. doi: 10.1016/S1473-3099(19)30612-7. Epub 2019 Dec 23. Lancet Infect Dis. 2020. PMID: 31879061 Free article.
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, Nyirenda R, Boles J, Thompson J, Tumukunde D, Chidziva E, Mambule I, Arribas JR, Easterbrook PJ, Hakim J, Walker AS, Mugyenyi P; EARNEST Trial Team. Paton NI, et al. N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274. N Engl J Med. 2014. PMID: 25014688 Free article. Clinical Trial.
Gender disparities and associated factors to intention to getting a second dose of COVID-19 AstraZeneca vaccine among adult populations in selected facilities of Lusaka, Zambia.
Jacobs C, Musonda NC, Tembo D, Simwaka M, Mwamba E, Munsaka SM, Shumba S. Jacobs C, et al. Among authors: mwamba e. PLOS Glob Public Health. 2022 Jul 20;2(7):e0000265. doi: 10.1371/journal.pgph.0000265. eCollection 2022. PLOS Glob Public Health. 2022. PMID: 36962377 Free PMC article.
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Paton NI, et al. Lancet HIV. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub 2017 May 8. Lancet HIV. 2017. PMID: 28495562 Free PMC article. Clinical Trial.
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Hakim JG, et al. Lancet Infect Dis. 2018 Jan;18(1):47-57. doi: 10.1016/S1473-3099(17)30630-8. Epub 2017 Nov 3. Lancet Infect Dis. 2018. PMID: 29108797 Free PMC article. Clinical Trial.